247237-43-0

Basic information

• Product Name: 5-Chloro-2-[(4-ethoxy-4-oxobutyl)[(4-methylphenyl)sulfonyl]amino]benzoic acid methyl ester
• Synonyms: 5-Chloro-2-[(4-ethoxy-4-oxobutyl)[(4-methylphenyl)sulfonyl]amino]benzoic acid methyl ester;methyl 5-chloro-2-(N-(4-ethoxy-4-oxobutyl)-4-methylphenylsulfonamido)benzoate
• CAS NO: 247237-43-0
• Molecular Formula: C₂₁H₂₄ClNO₆S
• Molecular Weight: 453.93636
• Mol File: 247237-43-0.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 580.4±60.0 °C(Predicted)
• Appearance: /
• Density: 1.30
• PKA: -4.31±0.50(Predicted)
• CAS DataBase Reference: 5-Chloro-2-[(4-ethoxy-4-oxobutyl)[(4-methylphenyl)sulfonyl]amino]benzoic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Chloro-2-[(4-ethoxy-4-oxobutyl)[(4-methylphenyl)sulfonyl]amino]benzoic acid methyl ester(247237-43-0)
• EPA Substance Registry System: 5-Chloro-2-[(4-ethoxy-4-oxobutyl)[(4-methylphenyl)sulfonyl]amino]benzoic acid methyl ester(247237-43-0)

Safety Data

• Hazardous Substances Data: 247237-43-0(Hazardous Substances Data)

Usage

Uses

Methyl 5-Chloro-2-[(4-ethoxy-4-oxobutyl)-(4-methylphenyl)sulfonylamino]benzoate can be used as a reactant in the synthesis of Tolvaptan (T536650) and its intermediates. Tolvaptan is a nonpeptide arginine vasopressin (AVP) V2 receptor antagonist.

Upstream product

• 2969-81-5 Ethyl 4-bromobutyrate 
• 247237-38-3 N-p-toluenesulfonyl-5-chloro-anthranilic acid methyl ester 
• 5202-89-1 4-chlorobenzenesulfonyl chloride 
• 2516-95-2 5-chloro-2-nitrobenzoic acid 
• 51282-49-6 methyl 5-chloro-2-nitrobenzoate 

Downstream Products

• 193686-76-9 7-chloro-1-(4-methylbenzenesulfonyl)-2,3,4,5-tetrahydro-1H-1-benzazepin-5-one 
• 1133419-00-7 ethyl 7-chloro-5-oxo-1-p-toluenesulfonyl-2,3,4,5-tetrahydro-1H-1-benzazepine-4-carboxylate 
• 154890-90-1 5-(N-allylamino)-7-chloro-1-[4-[(2-methylbenzoyl)amino]benzoyl]-2,3,4,5-tetrahydro-1H-1-benzazepine 
• 247237-98-5 7-chloro-1-[3-chloro-4-[(2-methylbenzoyl)amino]benzoyl]-5-oxo-2,3,4,5-tetrahydro-1H-1-benzazepine 
• 137978-52-0 7-chloro-1-[3-methoxy-4-[(2-methylbenzoyl)amino]benzoyl]-5-oxo-2,3,4,5-tetrahydro-1H-1-benzazepine 
• 137974-15-3 7-chloro-1-[2-methoxy-4-[(2-methylbenzoyl)amino]benzoyl]-5-oxo-2,3,4,5-tetrahydro-1H-1-benzazepine 
• 137973-76-3 MOP-21826 
• 137973-86-5 7-chloro-1-[2-chloro-4-[(2-methylbenzoyl)amino]benzoyl]-5-oxo-2,3,4,5-tetrahydro-1H-1-benzazepine 
• 137973-34-3 7-chloro-5-(N-methylamino)-1-[4-[(2-methylbenzoyl)amino]benzoyl]-2,3,4,5-tetrahydro-1H-1-benzazepine 
• 137977-35-6 7-chloro-1-[4-[(2-methylbenzoyl)amino]benzoyl]-5-oxo-2,3,4,5-tetrahydro-1H-1-benzazepine 
• 247237-81-6 5-allyloxy-7-chloro-1-(4-nitrobenzoyl)-2,3,4,5-tetrahydro-1H-1-benzazepine 
• 247237-89-4 7-chloro-1-(3-chloro-4-nitrobenzoyl)-5-oxo-2,3,4,5-tetrahydro-1H-1-benzazepine 
• 137982-83-3 7-chloro-1-(3-methoxy-4-nitrobenzoyl)-5-oxo-2,3,4,5-tetrahydro-1H-1-benzazepine 

Relevant articles and documents

PROCESS FOR PREPARING TOLVAPTAN INTERMEDIATES

The present invention provides a novel process for the preparation of 7-chloro-2,3,4,5-tetrahydro-1H-1-benzazepin-5-one. The present invention also provides an improved process for the preparation of 7-chloro-1-(2-methyl-4-nitrobenzoyl)-5-oxo-2,3,4,5-tetrahydro-1H-1-benzazepine. The present invention further provides an improved process for the preparation of 7-chloro-1-[2-methyl-4-[(2-methylbenzoyl)amino]benzoyl]-5-oxo-2,3,4,5-tetrahydro-1H-1-benzazepine.

7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoylamino)benzoyl]-2,3,4,5- tetrahydro-1H-1-benzazepine (OPC-41061): A potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist

We previously reported a series of benzazepine derivatives as orally active nonpeptide arginine vasopressin (AVP) V2 receptor antagonists. After the lead structure OPC-31260 was structurally evaluated and optimized, the introduction of the 7-Cl moiety on the benzazepine and 2-CH3 on the aminobenzoyl moiety enhanced its oral activity. The new AVP-V2 selective antagonist OPC-41061 was determined to be a potent and orally active agent. Copyright (C) 1999 Elsevier Science Ltd.